SAC Meeting Calendar
Newest Background Analyses
Search by Tag
- AAC
- AADPAC
- ACHDNC
- ACPS-CP
- AIDAC
- alogliptin
- AMDAC
- Amgen
- ankylosing spondylitis
- anti-hypertensives
- antibacterial
- APAC
- asthma
- AstraZeneca
- biosimilar
- bladder cancer
- blood donation
- Boehringer Ingelheim
- BPAC
- BRUDAC
- cancer
- Celltrion
- CFTR potentiator
- CLIAC
- CRDAC
- Crohn's disease
- CT-P13
- CTGTAC
- Cystic Fibrosis
- cytolitic
- diabetes
- DODAC
- DSRM
- Duchenne muscular dystrophy
- Eli Lilly
- EMDAC
- epidural steroid injections
- eteplirsen
- ezetimibe
- FDA
- GlaxoSmithKline
- HHS
- high cholesterol
- hypoactive sexual desire disorder
- infection
- infliximab
- influenza
- invasive aspergillosis
- iron deficiency
- ivacaftor
- liraglutide
- major depressive disorder
- melanoma
- Merck
- MIDAC
- monoclononal antibodies
- NDAC
- necitumumab
- neutropenia
- Novartis
- Novo Nordisk
- ODAC
- oncolytics
- opioid
- PADAC
- pain
- panobinostat
- Parkinsons disease
- PCAC
- PCNS
- PCSK9 inhibitor
- PDAC
- PEDAC
- pediatric
- pediatric anesthesia
- Pfizer
- Psoriasis
- psoriatic arthritis
- Purdue Pharma
- RCAC
- reduce CV risk
- reversal of neuromuscular blockade
- RO5503781
- Rockwell Medical
- SACHRP
- Sandoz
- Sanofi Aventis
- Sarepta Therapeutics
- SBFDA
- sugammadex
- Takeda
- talimogene laherparepvec
- testosterone
- testosterone replacement therapy
- Teva
- The Medicines Company
- TSEAC
- vaccines
- Vertex Pharmaceuticals
- VRBPAC
Selinexor tablets, submitted by Karyopharm Therapeutics, Inc., for use, in combination with dexamethasone, in the treatment of patients with relapsed refractory multiple myeloma who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor, at least one immunomodulatory agent, and an anti-CD38 monoclonal antibody